Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
FDA Advisory Committee Recommends Approval of Shire’s Prucalopride (SHP555) for Chronic Idiopathic Constipation | ||||||||||||||||||||||||||
By: Nasdaq / GlobeNewswire - 18 Oct 2018 | Back to overview list |
|||||||||||||||||||||||||
Intended for U.S. Audience FDA Advisory Committee Recommends Approval of Shire’s Prucalopride (SHP555) for Chronic Idiopathic Constipation If FDA grants approval, prucalopride will be the only readily available 5-HT4 receptor agonist1 in the U.S. for chronic idiopathic constipation in adults; FDA is anticipated to make a final decision by the end of December Cambridge, Mass. – October 18, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted unanimously (10 to 0) that the risk-benefit profile of prucalopride supports the approval of this New Drug Application (NDA). The FDA will take the advisory committee’s recommendation into consideration when the agency makes a final determination. The Prescription Drug User Fee Act (PDUFA) action date for prucalopride is December 21, 2018. The advisory committee also voted unanimously (10 to 0) that the potential risk of cardiovascular adverse events with the use of prucalopride in adults with CIC has been adequately addressed by Shire. Prucalopride, a serotonin type 4 (5-HT4) receptor agonist, is a gastrointestinal prokinetic agent that stimulates colonic peristalsis, increasing bowel motility.2,[3],[4],[5] Drugs similar to prucalopride have been associated with adverse cardiovascular (CV) events in the past. “We are pleased with the advisory committee’s vote today supporting prucalopride for the treatment of adults with chronic idiopathic constipation in the U.S., and will continue working with the FDA during the final stages of its review,” said Andreas Busch, Ph.D., Head of Research and Development at Shire. “This investigational compound reinforces Shire’s long-standing heritage in gastrointestinal conditions and deep in-house capabilities in the category.” Prucalopride has been studied in more than 90 clinical trials worldwide over the last 20 years, including six key studies by which the advisory committee made its recommendation today. The advisory committee reviewed data included in the prucalopride NDA, specifically five main Phase 3 and one Phase 4 double-blind, placebo-controlled clinical trials. An integrated analysis of these six main randomized, controlled clinical trials evaluated the global efficacy and safety of prucalopride 2 mg daily in men and women with chronic constipation; study designs across the trials were similar. Overall, there were 2,484 adult patients included in the integrated efficacy analysis and 2,552 adult patients included in the integrated safety analysis; all patients included received prucalopride less than or equal to 2 mg daily or placebo.6 The committee also reviewed results from an observational, pharmacoepidemiology safety study that Shire sponsored to estimate the risk, as measured by the pooled adjusted incidence rate ratio (IRR), of major adverse CV events (MACE) in adult new users of prucalopride compared to adult new users of polyethylene glycol (PEG). MACE included hospitalization for acute myocardial infarction or stroke and in-hospital CV death. Study data was from real-world settings in the United Kingdom and Sweden. This pooled analysis included over 35,000 patients with chronic constipation treated with prucalopride or PEG in a 1- to- 5 ratio.7 For the observational, pharmacoepidemiology safety study, the pooled adjusted IRR for MACE was 0.64 (95% CI, 0.36, 1.14)8 in this mostly female (>90%) patient population where many were aged 55 years or younger, which excluded a threefold increase risk of MACE in patients using prucalopride compared with PEG. The average total duration of use was over 170 days for prucalopride and over 80 days for PEG.7 There are an estimated 35 million adults in the U.S. with chronic idiopathic constipation.9,[10]* The condition is characterized by difficult, infrequent or incomplete passage of stools over a prolonged period and a range of symptoms, which may include abdominal pain and/or bloating.11 There are many causes, and one of the possible underlying problems is an impairment or dysfunction of the gut’s ability to move, by contracting and releasing, naturally.12 Supporting Clinical Data About Prucalopride Prucalopride is currently approved and available in the European Union (EU) where it is marketed by Shire as Resolor®, indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.13 Prucalopride is also available in several other countries outside of Europe. For further information please contact:
NOTES TO EDITORS About Shire Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics. Forward-Looking Statements Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, projected revenues, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:
a further list and description of risks, uncertainties and other matters can be found in Shire’s most recent Annual Report on Form 10-K and in Shire’s subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in “ITEM1A: Risk Factors”, and in Shire’s subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire’s website. All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise. *This represents ~14% of the U.S. population as of July 1, 2017 Census Bureau Data. 1 Briejer MR et al. Eur J Pharmacol 2001;423:71–83. 2 Camilleri, M, et al. 2008 A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation. N 3 Miner, PB, Camilleri, M., Burton, D., et. al. Prucalopride Induces High-Amplitude Propagating 4 DeSchryver, et. al. The effects of the specific 5HT4 receptor agonist, prucalopride, on colonic motility in 5 Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the 6 Camilleri M, et al. Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of 7 Non-Interventional Cohort Study of the Relative Incidence of Major Cardiovascular Events Among 8 Shire Errata to Shire’s FDA Briefing Document. October 18, 2018. 9 U.S. Census Data. Available at: https://www.census.gov/quickfacts/fact/table/US/PST045216. 2017. 10 Suares NC, Ford AC. Prevalence of, and Risk Factors for, Chronic Idiopathic Constipation in the 11 Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology 2016;150:1393–407. 12 Ford AC, Moayyedi P, Lacy BE, et. al. American College of Gastroenterology Monograph on the 13 Resolor® (prucalopride), EU Summary of Product Characteristics, December 2015. |
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |